Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib

Main Article Content

Jennifer Fu
Alexander Egeberg
Susan Holmes
Sergio Vano-Galvan
Martin Steinhoff
Roger Edwards
Ranjit Nagra
Robert Wolk
Helen Tran
Ernest Law

Keywords

ritlecitinib, alopecia areata

References

1. Islam N, et al. Autoimmun Rev. 2015;14:81-89.

2. Anderson P, et al. EADV 2022. Abstract 1695.

3. King B, et al. Lancet. 2023;401:1518-1529.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.292

Article Details

How to Cite
Fu, J., Egeberg, A., Holmes, S., Vano-Galvan, S., Steinhoff, M., Edwards, R., Nagra, R., Wolk, R., Tran, H. ., & Law, E. (2023). Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib. SKIN The Journal of Cutaneous Medicine, 7(6), s292. https://doi.org/10.25251/skin.7.supp.292
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)